Travere Therapeutics (TVTX) Restructuring Costs (2016 - 2024)
Travere Therapeutics' (TVTX) quarterly Restructuring Costs came in at $1.4 million in Q4 2024, down 88.02% YoY from $11.4 million in Q1 2024, and up 1009.76% on a QoQ basis from $123000.0 in Q3 2024.
Powered by 
Analysis
Travere Therapeutics (TVTX) Restructuring Costs (2016 - 2024) Analysis & Trends
Travere Therapeutics (TVTX) has 5 years of Restructuring Costs data on file, last reported at $1.4 million in Q4 2024.
- Quarterly Restructuring Costs fell 88.02% year-over-year to $1.4 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $1.4 million (down 89.02% YoY) and the FY2024 annual result came in at $2.4 million, down 78.94% from the prior year.
- Restructuring Costs advanced to $1.4 million in Q4 2024, from $123000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $11.4 million in Q4 2023 to a low of $123000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 6.11 Bn | 6.11 Bn | 162.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 123,000.00 |
| Jun 30, 2024 | 653,000.00 |
| Mar 31, 2024 | 259,000.00 |
| Dec 31, 2023 | 11.39 Mn |
| Dec 31, 2017 | 997,000.00 |
| Sep 30, 2017 | 1.13 Mn |
| Jun 30, 2017 | 981,000.00 |
| Mar 31, 2017 | 498,000.00 |
| Sep 30, 2016 | 5.21 Mn |